Table 2.

HbA_1c changes from baseline to end point, proportion of patients with positive responses to predefined HbA_1c criteria and fasting plasma glucose changes to end point

	Nateglinide + metformin n = 129	Gliclazide + metformin n = 118
Baseline HbA1c (%), mean ± sd	7.66 ± 0.59	7.57 ± 0.57
Change, least squares mean ± se	−0.41 ± 0.08	−0.57 ± 0.08
P-value for change	< 0.001	< 0.001
Treatment difference, mean ± sd	0.17 ± 0.10
P-value for treatment difference	0.099
Response rates, n (%)
Reduction of HbA1c ≥ 0.5% from baseline	63 (48.8)	58 (49.2)
End point HbA1c < 7.0%	45 (34.9)	55 (46.6)
Reduction of HbA1c ≥ 0.5% from  baseline or end point HbA1c < 7.0%	75 (58.1)	71 (60.2)
Baseline FPG (mmol/l), mean ± sd	8.49 ± 1.49	8.65 ± 1.49
Change, least squares mean ± se	−0.63 ± 0.17	−0.82 ± 0.18
P-value for change	< 0.001	< 0.001
Treatment difference, mean ± sd	0.19 ± 0.21
P-value for treatment difference	0.375